Updates are available Correction dated 2025-03-12
Click to view Correction: https://doi.org/10.1007/s00403-025-04136-8
-
Authors
Choung, Rok Seon
Ramakrishna, Jyoti
Pradhan, Vivek
King, Brett
Guttman-Yassky, Emma
Peeva, Elena
Murray, Joseph A.
- License Information
-
More Information
Article History
Received: 30 October 2024
Revised: 27 December 2024
Accepted: 29 December 2024
First Online: 18 January 2025
Change Date: 12 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00403-025-04136-8
Declarations
:
: JR, VP, and EP are employees of Pfizer and hold stock and/or stock options with Pfizer. BK has received honoraria and/or consultation fees from AbbVie, AltruBio, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol Myers Squibb, Concert Pharmaceuticals, Equillium, Horizon Therapeutics, Eli Lilly, Incyte, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra, Pfizer, Regeneron, Sanofi Genzyme, TWi Biotechnology, and Viela Bio. He previously served on speaker bureaus for AbbVie, Incyte, Eli Lilly, Pfizer, Regeneron, and Sanofi Genzyme. EG received research grants from Leo Pharma, Pfizer, Amgen, GSK, Incyte, Sanofi, Bristol Meyers Squibb, Aslan, Regeneron, Anaptysbio, Concert, Janssen, Q32Bio, Abbvie, Eli-Lilly, Arcutis, Inmagene Bio.; and consultancy fees from Abbvie, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics Limited, Artax Biopharma Inc., Astria, Bristol Meyers Squibb, Boerhinger-Ingelhiem, Calliditas, Cara Therapeutics, Celldex, Centrexion Therapeutics Corporation, Connect Biopharm, Coty, DBV Technologies, Eli Lilly, Enveda Biosciences, Escient Pharmaceuticals, Inc., Fairmount Funds Management LLC, FL2022-001, Inc., Galderma, Gate Bio, Google Ventures (GV), GSK Immunology, Incyte, Inmagene, Janssen Biotech, Jasper Therapeutics, Kymera Therapeutics, Kyowa Kirin, Leo Pharma, Matchpoint Therapeutics, Merck, Nektar Therapeutics, Novartis Pharmaceuticals, NUMAB Therapeutics AG, Nuvig, OrbiMed Advisors LLC, OTSUKA, Pfizer, Pharmaxis Ltd, Pioneering Medicine VII, Inc., Proteologix US Inc, RAPT, RayThera, Inc, Regeneron Pharmaceuticals, RibonTherapeutics, Inc., Rocatinlimab, Sanofi, SATO, Schrödinger, Inc., Sitryx, Sun Pharma Advanced Research Company (SPARC), Takeda, Teva Branded Pharmaceutical Products R&D, Inc, UCB, Ventyx Biosyences. JAM has received research grants from Nexpep/ImmusanT, National Institutes of Health, Immunogenix, Takeda Pharmaceutical, Allakos, ProventionBio, Oberkotter Foundation, and 9 m, Inc.; contract (to institution) from Kanyos Bio (a wholly owned subsidiary of Anokion); and consultancy fees from Johnson and Johnson, Bristol Myers Squibb, Intrexon Corporation, Dren Bio, Neoleukin, Reistone pharma, Immunic Therapeutics, Senda Biosciences, Brightseed Bio, Chugai Pharma, Alimentiv, Equillium, Ukko, Vial Health Technologies and has received royalties from Torax Medical and Evelo. The other authors have no conflicts of interest to declare.
